Emerging topical therapies to treat pigmentary disorders: an evidence-based approach

References

• Cayce KA, McMichael AJ, Feldman SR. Hyperpigmentation: an overview of the common afflictions. Dermatol Nurs. 2004;16(5):401–406. 413–416; quiz 417.
   PubMedGoogle Scholar
• Shin JW, Park KC. Current clinical use of depigmenting agents. Dermatol Sin. 2014;32(4):205–210.
   Web of Science ®Google Scholar
• Vashi NA, Kundu RV. Facial hyperpigmentation: causes and treatment. Br J Dermatol. 2013;169 (Suppl):41–56.
   PubMedGoogle Scholar
• Ertam I, Mutlu B, Unal I, et al. Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. J Dermatol. 2008;35(9):570–574.
   PubMed Web of Science ®Google Scholar
• Zhu W, Gao J. The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. J Investig Dermatol Symp Proc. 2008;13(1):20–24.
   PubMedGoogle Scholar
• Morag M, Nawrot J, Siatkowski I, et al. A double-blind, placebo-controlled randomized trial of Serratulae quinquefoliae folium, a new source of β-arbutin, in selected skin hyperpigmentations. J Cosmet Dermatol. 2015;14(3):185–190.
   PubMed Web of Science ®Google Scholar
• Choi S, Lee SK, Kim JE, et al. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol. 2002;27(6):513–515.
   PubMed Web of Science ®Google Scholar
• Telang PS. Vitamin C in dermatology. Indian Dermatol Online J. 2013;4(2):143–146.
   PubMedGoogle Scholar
• Hwang SW, Oh DJ, Lee D, et al. Clinical efficacy of 25% L-ascorbic acid (C’ensil) in the treatment of melasma. J Cutan Med Surg. 2009;13(2):74–81.
   PubMed Web of Science ®Google Scholar
• Huh CH, Seo KI, Park JY, et al. A randomized, double-blind, placebo-controlled trial of vitamin C iontophoresis in melasma. Dermatology. 2003;206(4):316–320.
   PubMed Web of Science ®Google Scholar
• Hollinger JC, Angra K, Halder RM. Are natural ingredients effective in the management of hyperpigmentation? A systematic review. J Clin Aesthet Dermatol. 2018;11(2):28–37.
   PubMedGoogle Scholar
• Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004;43(8):604–607.
   PubMed Web of Science ®Google Scholar
• Al-Niaimi F, Chiang NYZ. Topical vitamin c and the skin: mechanisms of action and clinical applications. J Clin Aesthet Dermatol. 2017;10(7):14–17.
   PubMedGoogle Scholar
• Burdock GA, Soni MG, Carabin IG. Evaluation of health aspects of kojic acid in food. Regul Toxicol Pharmacol. 2001;33(1):80–101.
   PubMed Web of Science ®Google Scholar
• Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20–31.
   PubMedGoogle Scholar
• Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147(1):20–31.
   PubMed Web of Science ®Google Scholar
• Bissett DL, Miyamoto K, Sun P, et al. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci. 2004;26(5):231–238.
   PubMedGoogle Scholar
• Navarrete-Solis J, Castanedo-Cazares JP, Torres-Alvarez B, et al. A double-blind, randomized clinical trial of niacinamide 4% versus hydroquinone 4% in the treatment of melasma. Dermatol Res Pr. 2011;2011:379173.
   PubMedGoogle Scholar
• Rolfe HM. A review of nicotinamide: treatment of skin diseases and potential side effects. J Cosmet Dermatol. 2014;13(4):324–328.
   PubMed Web of Science ®Google Scholar
• Lowe NJ, Rizk D, Grimes P, et al. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther. 1998;20(5):945–959.
   PubMed Web of Science ®Google Scholar
• Balina LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30(12):893–895.
   PubMed Web of Science ®Google Scholar
• Mazurek K, Pierzchała E. Comparison of efficacy of products containing azelaic acid in melasma treatment. J Cosmet Dermatol. 2016;15(3):269–282.
   PubMed Web of Science ®Google Scholar
• Canavan TN, Chen E, Elewski BE. Optimizing non-antibiotic treatments for patients with acne: a review. Dermatol Ther. 2016;6(4):555–578.
   Web of Science ®Google Scholar
• Kasraee B, Mansouri P, Farshi S. Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman’s formula. J Cosmet Dermatol. 2019;18(1):293–295.
   PubMed Web of Science ®Google Scholar
• Farshi S, Mansouri P, Kasraee B. Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch as a new measurement method: a randomized double blind placebo controlled study. J Dermatol Treat. 2018;29(2):182–189.
   PubMed Web of Science ®Google Scholar
• Mansouri P, Farshi S, Hashemi Z, et al. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015;173(1):209–217.
   PubMed Web of Science ®Google Scholar
• Chandra M, Levitt J, Pensabene CA. Hydroquinone therapy for post-inflammatory hyperpigmentation secondary to acne: not just prescribable by dermatologists. Acta Derm Venereol. 2012;92(3):232–235.
   PubMed Web of Science ®Google Scholar
• Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20(7):781–787.
   PubMed Web of Science ®Google Scholar
• Ennes SBP, Paschoalick RC, Alchorne MMDA. A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. J Dermatolog Treat. 2000;11(3):173–179.
   Web of Science ®Google Scholar
• Haddad AL, Matos LF, Brunstein F, Ferreira LM, et al. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int J Dermatol. 2003;42(2):153–156.
   PubMed Web of Science ®Google Scholar
• Vanaman Wilson MJ, Jones IT, Bolton J, et al. A randomized, investigator-blinded comparison of two topical regimens in Fitzpatrick skin types III–VI with moderate to severe facial hyperpigmentation. J Drugs Dermatol. 2017;16(11):1127–1132.
   PubMed Web of Science ®Google Scholar
• Stephens TJ, Babcock M, Bucay V, et al. Split-face evaluation of a multi-ingredient brightening foam versus a reference control in women with photodamaged facial skin. J Clin Aesthet Dermatol. 2018;11(10):24–28.
   PubMedGoogle Scholar
• Sarkar R, Arora P, Garg KV. Cosmeceuticals for hyperpigmentation: what is available? J Cutan Aesthet Surg. 2013;6(1):4–11.
   PubMedGoogle Scholar
• Westerhof W, Kooyers TJ. Hydroquinone and its analogues in dermatology – a potential health risk. J Cosmet Dermatol. 2005;4(2):55–59.
   PubMedGoogle Scholar
• Levy LL, Zeichner JA. Management of acne scarring, part II: a comparative review of non-laser-based, minimally invasive approaches. Am J Clin Dermatol. 2012;13(5):331–340.
   PubMed Web of Science ®Google Scholar
• Dharmana S. Review of topical lightening agents. Pigment Disord. 2014;1:145.
   Google Scholar
• Mukherjee S, Date A, Patravale V, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327–348.
   PubMed Web of Science ®Google Scholar
• Truchuelo MT, Jimenez N, Jaen P. Assessment of the efficacy and tolerance of a new combination of retinoids and depigmenting agents in the treatment of melasma. J Cosmet Dermatol. 2014;13(4):261–268.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma. a vehicle-controlled, clinical trial. Br J Dermatol. 1993;129(4):415–421.
   PubMed Web of Science ®Google Scholar
• Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328(20):1438–1443.
   PubMed Web of Science ®Google Scholar
• Sacchidanand SA, Lahiri K, Godse K, et al. Synchronizing pharmacotherapy in acne with review of clinical care. Indian J Dermatol. 2017;62(4):341–357.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Gover MD, Nouri K, et al. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55(6):1048–1065.
   PubMed Web of Science ®Google Scholar
• Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72(1):67–72.
   PubMed Web of Science ®Google Scholar
• Grimes P, Kelly AP, Torok H, et al. Community-based trial of a triple-combination agent for the treatment of facial melasma. Cutis. 2006;77(3):177–184.
   PubMed Web of Science ®Google Scholar
• Torok HM, Jones T, Rich P, et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis. 2005;75(1):57–62.
   PubMed Web of Science ®Google Scholar
• Schulte BC, Wu W, Rosen T. Azelaic acid: evidence-based update on mechanism of action and clinical application. J Drugs Dermatol. 2015;14(9):964–968.
   PubMed Web of Science ®Google Scholar
• Grimes PE, Ijaz S, Nashawati R, et al. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol. 2019;5(1):30–36.
   PubMedGoogle Scholar
• Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111(1):40–48.
   PubMedGoogle Scholar
• Lynde CB, Kraft JN, Lynde CW. Topical treatments for melasma and postinflammatory hyperpigmentation. Ski Ther Lett. 2006;11(9):1–6.
   PubMedGoogle Scholar